Navigation Links
Cepheid Launches First On-Demand Molecular Diagnostic Test for Clostridium Difficile Into European Market
Date:11/10/2008

Test Simultaneously Identifies and Differentiates More Virulent 027 Strain

from Common Strains

SUNNYVALE, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced the release of Xpert(TM) C. difficile as a European CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices. For the first time, European hospitals will have access to a reliable, rapid test for Clostridium difficile, which simultaneously detects and identifies the commonly occurring strains and specifically identifies the more virulent Type 027 strain. The new 50-minute test runs on Cepheid's GeneXpert(R) System, the world's leading HAI molecular testing platform, and eliminates the need for multiple tests using less reliable methods.

Based on published incidence rates, there are approximately 58,000 annual cases of Clostridium difficile-associated disease (CDAD) in the United Kingdom. A recent health statistics report on deaths involving C. difficile in England and Wales showed the annual number of deaths rising by approximately 55 percent to nearly 8,500 in 2007.

"C. difficile is a horrific infection for a patient to deal with, especially as it is most common amongst the elderly and infirm, or those who are already seriously ill and have a weakened immune system," said Professor Richard James, Director of the Centre for Healthcare Associated Infections, University of Nottingham. "C. difficile infected patients are a source of transmission to other patients, therefore it is important that infected patients are detected as early as possible in order to minimize the impact of the outbreak. Rapid molecular testing, providing wholly accurate results in less than an hour, when combined with isolation of infected patients, provides an important new weapon in our battle against healthcare associated infections."

The more virulent C. difficile Type 027 strain has been reported in 16 European coun
'/>"/>

SOURCE Cepheid
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cepheid to Present at ThinkEquity Partners 5th Annual Growth Conference
2. Cepheid Schedules Teleconference and Webcast for Third Quarter 2007 Results
3. Cepheid and Broadlane Sign Group Purchasing Contract for GeneXpert(R) Systems and Xpert(TM) Molecular Diagnostic Tests, Including Xpert MRSA
4. Cepheid to Present at the Needham Tenth Annual Growth Stock Conference
5. Cepheid Comments on Study Regarding MRSA Surveillance Reported in the Journal of the American Medical Association
6. Cepheid Selected as Vendor of Choice by Connecticut Hospital Association Shared Services Program for Molecular MRSA Surveillance Testing
7. Cepheid Reports Record Revenue of $44.8 Million
8. Cepheid Signs Group Purchasing Contract With Premier Healthcare Alliance, One of the Largest U.S. Group Purchasing Organizations
9. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
10. UPMC Health Plan Launches New Personal Health Record
11. HealthInsuranceFinders.com Launches Video Contest for Young Directors

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...wire-USNewswire/--AnarticlebyJanetWoodcock,M.D.,di...,titled"ADifficultBalance-PainManagement,DrugSafet...nglandJournalofMedicine. ,, (Logo: http://www.n...nthearticle,WoodcockdiscussesFDAeffortstostrikeaba...tandmanagingtherisksposedbyvariousanalgesics.Asexa...
(Date:11/25/2009).../--TheBayAreaAirQualityManagementDistrictisissuing...Alert forThursday,November26,2009whichbansburnin...indoorsandoutdoors. ,, "Cold,stillweatherwillco...adbent,executiveofficeroftheAirDistrict."We,reaski...rsandfellowcommunitymembersthisThanksgiving,andnot...
(Date:11/25/2009)...ncer who were treated with cisplatin-based chemoth...ological side effects and Raynaud-like phenomena, ...ccording to a new study published online November ...e . , Marianne Brydy, M.D., of the Department of...n, Norway, and colleagues conducted a cross-sectio...
(Date:11/25/2009)...ut of a collaboration between UCLA engineers and p...ly 10 million Americans who suffer from peripheral... of the arteries, peripheral arterial disease, or ...owed arteries reduce blood flow to the limbs. The ...sease, heart attack and stroke, and its progressio...
(Date:11/25/2009)...rt to draw definite conclusions, experts say, , ...In diabetic patients with blocked coronary arterie...t one year whether patients undergo bypass surgery... report. , Bypass surgery has been the standard...ery disease. However, less invasive approaches suc...
Breaking Medicine News(10 mins):Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Stenting May Equal Bypass for Diabetic Heart Patients 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 3
...ce" Includes Allscripts, Cisco, Citrix, Dell, Inte...er Education Programs Across the U.S. , , CHICAGO... of a coalition of technology innovation leaders w...Act details President Obama,s plan to improve heal...
...r,* Advanced Ribbon Dressing Features Hydrofiber(R..., a world-leading developer and marketer of innova...al care, announced today the launch of AQUACEL(R) ...oved wound dressing also offers reduced shrinkage ...
... 14 drugstore.com , inc. (Nasdaq: DSCM ), a le...nd pharmacy products, today announced that Dawn Le...board, and Tracy Wright, chief finance officer, wi...drugstore.com(TM) presentation will take place on ...
...4 Nile Therapeutics, Inc. (Nasdaq: NLTX ), ...apeutics for heart failure patients, today announc... , Update on CD-NP , , In March, Nile announce...nt to Nile, and in a follow-up teleconference, the...
...r Research Month activities include spring dedicat...VILLE, Ala., May 14 Today Intergraph(R) and the H... honor three remarkable cancer survivors at the In... at this inspirational gathering which coincided w...
...blacks less likely to suffer atrial fibrillation ,...hites are more likely than blacks to experience at...blacks have a higher prevalence of risk factors su...bers, or atria, quiver chaotically instead of beat...
Other Medicine News:Health News:Leading Healthcare Technology Companies Launch National Physician Education Program on Stimulus and Electronic Health Records 2Health News:Leading Healthcare Technology Companies Launch National Physician Education Program on Stimulus and Electronic Health Records 3Health News:Leading Healthcare Technology Companies Launch National Physician Education Program on Stimulus and Electronic Health Records 4Health News:Leading Healthcare Technology Companies Launch National Physician Education Program on Stimulus and Electronic Health Records 5Health News:Leading Healthcare Technology Companies Launch National Physician Education Program on Stimulus and Electronic Health Records 6Health News:Leading Healthcare Technology Companies Launch National Physician Education Program on Stimulus and Electronic Health Records 7Health News:Leading Healthcare Technology Companies Launch National Physician Education Program on Stimulus and Electronic Health Records 8Health News:Leading Healthcare Technology Companies Launch National Physician Education Program on Stimulus and Electronic Health Records 9Health News:Leading Healthcare Technology Companies Launch National Physician Education Program on Stimulus and Electronic Health Records 10Health News:ConvaTec Launches New AQUACEL(R) Ag Dressing with Strengthening Fiber 2Health News:ConvaTec Launches New AQUACEL(R) Ag Dressing with Strengthening Fiber 3Health News:ConvaTec Launches New AQUACEL(R) Ag Dressing with Strengthening Fiber 4Health News:ConvaTec Launches New AQUACEL(R) Ag Dressing with Strengthening Fiber 5Health News:drugstore.com, inc. to Present at the Upcoming JMP Securities Research Conference 2Health News:Nile Therapeutics Reports 2009 First Quarter Financial Results 2Health News:Nile Therapeutics Reports 2009 First Quarter Financial Results 3Health News:Nile Therapeutics Reports 2009 First Quarter Financial Results 4Health News:Courageous Cancer Survivors Honored at Intergraph(R) Garden of Hope 2Health News:Courageous Cancer Survivors Honored at Intergraph(R) Garden of Hope 3Health News:Courageous Cancer Survivors Honored at Intergraph(R) Garden of Hope 4Health News:Courageous Cancer Survivors Honored at Intergraph(R) Garden of Hope 5Health News:Courageous Cancer Survivors Honored at Intergraph(R) Garden of Hope 6Health News:Courageous Cancer Survivors Honored at Intergraph(R) Garden of Hope 7Health News:Risk Factor for Stroke More Common Among Whites 2
(Date:11/25/2009)...ov.25/PRNewswire/--PraxisElectronicMedicalRecordsr...ilyPhysicians,(AAFP)FamilyPracticeManagement(FPM)2...lity,healthmaintenance,anddiseasemanagement,allcri...d#1amongdoctorsindicatingtheirEMRhadapositiveeffec...numberoneinthecountryinprovidingexcellenttraininga...
(Date:11/25/2009).../PRNewswire-FirstCall/--ERT(Nasdaq: ERES ),announc...entandCEO,andKeithSchneck,theCompany,sExecutiveVic...ualPiperJaffrayHealthCareConferenceat1:30PMESTonDe...dpartiesmayaccessthepresentationbyvisitingtheCompa...astmayalsobeaccessedat http://www.corporate-ir.net...
(Date:11/25/2009)....25/PRNewswire-USNewswire/--RemediumTechnologiesIn...psseverebleeding,wonfirstprizeand$10,000intheMostP...llenge2009,companyofficialsannouncetoday. ,, Se...edium,steampitchedtheirinventionattheGSCSecuritySu..., Remedium( www.remediumtechnologies.com )isdevel...
Breaking Medicine Technology:Praxis EMR Wins Top Rankings in 2009 AAFP EHR User Satisfaction Survey 2ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3Psoriasis Raises Risk of Heart Attack Stroke Death 48954 1Psoriasis Raises Risk of Heart Attack Stroke Death 48954 2First Spine Technology Awards to Recognize Excellence and Innovation 48952 1First Spine Technology Awards to Recognize Excellence and Innovation 48952 2MUHC researcher awarded 24500 000 to study pathogenesis of infectious disease 48951 1MUHC researcher awarded 24500 000 to study pathogenesis of infectious disease 48951 2
...st-hoc analysis shows nearly nine out of ten patie... at the end of 12 months, WASHINGTON, D.C., May 22... III, open-label 12-14 month extension study (303)...ogy (BSG) meeting,in Glasgow, Scotland in March 20...olerated in mild to moderate UC,patients. Today, s...
...MIRA Data Showed 57 Percent Reduction in Risk of H... One Year, ABBOTT PARK, Ill., May 22, 2007 /PRNews...from a post-hoc analysis of a pivotal study,presen...n,Washington, D.C. showing patients with moderate ...MIRA(R) (adalimumab) maintenance,therapy were almo...
Other Medicine Technology:Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 2Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 3Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 4Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 5Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 6Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 7Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 8New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 2New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 3New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 4New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 5New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 6New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 7
...t alternative to Equalizers, the patented EXP Syst...tween two different vessel configurations. With th...ly and easily adjusted for test tubes (and microce...gn for Unparalleled Comfort Pick one of our pipet...
...bility The Equalizer 384 includes all the revolu...le and equal tip spacing, choice of two software p...ration capabilities. In addition, this model allow...loading and accessing many gels and for use with 3...
PrismPipette 96-lane Starter Set
BioPette E Electronic Multi-Channel Pipettor, 10-200l
Medicine Products: